

Iowa Medicaid Drug Utilization Review (DUR) Commission Meeting

November 6, 2019

**Location: Iowa State Capitol Room 116
1007 E. Grand Ave
Des Moines, Iowa, 50319**

Time: 9:30 a.m. – 1:30 p.m.

Final Agenda

1. Welcome & Introductions
 - a) Commission Members and Staff
2. Commission Business
 - a) Approval of the Minutes
 - b) August 2019 DUR Recommendation Letter to DHS
 - c) August 2019 P&T Committee Recommendation Letter to DUR
 - d) Follow-Up from Previous Meeting(s)
 - e) Commission Recommendations for Retrospective DUR Agenda Topics
3. IME Pharmacy Update
4. Prevalence Report Summaries
 - a) Amerigroup
 - b) Iowa Total Care
 - c) Fee-for-Service
 - d) Comparative Summary
5. Public Comment* (See Speaker Conflict of Interest Disclosure Form)
6. ProDUR Edits
 - a) Review of Current & Proposed Opioid Quantity Limits - Initial Review
 - b) Gabapentinoid Quantity Limit – Second Review
7. Retrospective DUR Proposals
 - a) High Dose Gabapentin
 - b) Duplicate SSRIs
8. Break (10 minutes)
9. Prior Authorization

- a) Annual Review of Prior Authorization Criteria
- b) Linezolid (Zyvox) – Initial Review
- c) Dupilumab (Dupixent) – Initial Review
- d) Biologicals for Axial Spondyloarthritis – Initial Review
- e) Ivabradine (Corlanor) – Initial Review
- f) Chronic Pain Syndromes – Consideration of PARemoval - Initial Review
- g) Anti-Diabetic Non-Insulin Agents – Initial Review
- h) Multiple Sclerosis Agents, Oral – Second Review
 - i. Cladribine (Mavenclad)
 - ii. Siponimod (Mayzent)
- i) Ospemifene (Osphena) – Second Review
- j) Abilify MyCite – Second Review
- k) CGRP Inhibitors – Second Review

10. Miscellaneous

- a) DUR Digest Vol. 32, No. 1 – Second Review
- b) MedWatch

11. Adjournment

*Individuals attending meetings of the DUR Commission shall have an opportunity to address the Commission. This opportunity will be granted once during the open portion of the meeting. In order to accommodate all interested parties, all speakers are requested to limit their comments to **5 minutes or less**. If you represent a drug manufacturer as an employee, as a contractor, as a member of the manufacturer's Speaker Bureau, or by any other means, we expect you to cover your individual product or entire product line in that five-minute time frame. Speakers who represent multiple manufacturers will share their 5 minutes with the other manufacturer representative(s) whose product they are speaking on.

www.iadur.org

For more information, contact the DUR Project Coordinator, Pamela Smith, R.Ph., at info@iadur.org or (515) 974-3131

**Next Meeting
March 4, 2020
Location TBD**